Trump tariffs hit Indian pharma stocks
Indian pharmaceutical stocks slid after US President Donald Trump unveiled a phased tariff plan for imported generic medicines, offering a two-year zero-tariff window beginning August 1, 2026, followed by 100% tariffs from August 2028 and 200% from August 2029, fueling concerns about US-facing revenue for Indian drugmakers. The move dragged the Nifty Pharma index and major exporters like Sun Pharma, Cipla and Dr Reddy’s lower as investors reassess long-term earnings amid the policy shift.
